Oneness Biotech Co Ltd 2023 AR2
The report outlines Oneness Biotech Co., Ltd.'s business operations, research and development progress, and corporate governance for the fiscal year 2023. Key highlights include the inclusion of its diabetic foot ulcer drug, Fespixon, in Taiwan's National Health Insurance and its approval in Singapore, Malaysia, and China. The company was also selected as a constituent of the Dow Jones Sustainability Indices (DJSI) emerging markets, ranking in the top 3% of the pharmaceutical industry. Financially, the company reported a consolidated after-tax net loss of NT$1,312,867 thousand, primarily due to the recognition of licensing obligations in the previous year.
Company: Oneness Biotech Co Ltd
Sector: Health Care
Country: Taiwan
Year: 2023
Type: AR2
Pages: 372
Oneness Biotech Co Ltd
Annual Report
The report outlines Oneness Biotech Co., Ltd.'s business operations, research and development progress, and corporate governance for the fiscal year 2023. Key highlights include the inclusion of its diabetic foot ulcer drug, Fespixon, in Taiwan's National Health Insurance and its approval in Singapore, Malaysia, and China. The company was also selected as a constituent of the Dow Jones Sustainability Indices (DJSI) emerging markets, ranking in the top 3% of the pharmaceutical industry. Financially, the company reported a consolidated after-tax net loss of NT$1,312,867 thousand, primarily due to the recognition of licensing obligations in the previous year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Workplace Fatalities
Employees